UNSPSC 51263173: Timolol anhydrous

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H24N4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5JKY92S7BR. The term TIMOLOL ANHYDROUS is an International Non-Proprietary Name or INN. Most nations, for tariff and trade purposes, schedule timolol anhydrous under HS 29349990. As of Q4 2014, TIMOLOL ANHYDROUS remains US FDA's Preferred Term for this commodity. Timolol anhydrous bears US NLM identifiers UMLS ID C2983887 and NCI Concept Code C90802.

SMILES: CC(C)(C)NC[C@@H](COC1C(NSN1)N2CCOCC2)O.

UNSPSC 51263173 Timolol anhydrous is a Commodity code that nominally covers a specific ophthalmic beta-blocker pharmaceutical, but the recent state and local opportunities tagged under it show minimal alignment with this narrow product scope. The Seminole County, Florida procurement (IFB60459723LAS) solicits naloxone and drug deactivation systems—opioid-reversal agents and medical waste management products unrelated to timolol—while the Texas Health and Human Services Commission RFI (HHS0017013) addresses direct-to-manufacturer prescription program design and pharmacy benefit contracting rather than procurement of any specific pharmaceutical commodity. The code appears to capture sporadic and misaligned state and local pharmaceutical and medical supply buying rather than dedicated sourcing of timolol products.

The issuing bodies include county health departments and state health agencies. Geographic activity is limited to Florida and Texas based on the recent opportunities. Seminole County's IFB for naloxone and drug deactivation systems, posted June 30, 2026 with a response deadline of July 26, 2026, requires quarterly deliveries and annual procurement of 1,900 naloxone units and 800 deactivation systems; the Texas HHS Commission's April 3, 2026 RFI (HHS0017013) seeks vendor information on direct pharmaceutical contracting and prescription fulfillment models rather than specific commodity procurement. No formal solicitations targeting timolol or related ophthalmic agents appear in the recent-opportunity record, suggesting the code may be inconsistently applied or underutilized for its intended pharmaceutical scope by state and local procurement offices.